This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: Entresto

August 2016 Br J Cardiol 2016;23:92

Correspondence: Sacubitril/valsartan: where should it sit in the heart failure pathway?

Robert Stevenson

Abstract

Sacubitril/valsartan (Entresto™, Novartis), the first angiotensin receptor blocker (ARB) and neprilysin inhibitor (NEP) combination – known as an angiotensin-receptor-neprilysin inhibitor (ARNI) – has recently been approved by the National Institute for Health and Care Excellence (NICE) in the treatment of patients with chronic heart failure.1 The guidance, largely based on results from the landmark PARADIGM- HF study,2 recommends sacubitril/valsartan as an “option” for symptomatic patients (New York Heart Association [NYHA] class II– IV) who have an ejection fraction of 35% or less and are established on a “stable dose” of an

| Full text

June 2016 Br J Cardiol 2016;23:51

NICE go-ahead for sacubitril/valsartan

BJCardio Staff

Abstract

Sacubitril/valsartan is the first of a new kind of drug called angiotensin receptor neprilysin inhibitors. NICE recognised sacubitril/valsartan as an innovative treatment, which it says “offers the potential to prevent deaths and reduce the more than 30,000 hospital admissions for this condition each year in England”.  It is the first non-cancer drug to be fast-tracked through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicines Scheme. The scheme aims to give patients with life threatening or seriously debilitating conditions access to medicines before they are licensed where there is a clear, unmet medi

| Full text

March 2016 Br J Cardiol 2016;23:10–11

In brief

BJCardio Staff

Abstract

Approval for new heart failure treatment A breakthrough drug for the treatment of chronic heart failure is now available in the UK.  The new drug sacubitril/valsartan (Entresto®, Novartis) has been approved for the treatment of adults with symptomatic heart failure with reduced left ventricular ejection fraction (HFREF). Sacubitril/valsartan – the first drug in the angiotensin receptor neprilysin inhibitor (ARNI) class of drugs – was found to be superior to an evidence-based dose of the angiotensin-converting enzyme (ACE) inhibitor, enalapril, in the PARADIGM-HF study, the largest heart failure study conducted to date. PARADIGM-HF (Pros

| Full text

December 2015 Br J Cardiol 2015;22:143–4

In brief

BJCardio Staff

Abstract

BHF to spend half a billion pounds on research A new research strategy has been launched by the British Heart Foundation (BHF), aiming to fund over half a billion pounds of new cardiovascular research over the next five years. The BHF’s new strategy includes a commitment to continue funding the best researchers working across all areas of cardiovascular disease research.  This includes a pledge by the BHF to help women stay in research after a review highlighted the underrepresentation of women in senior cardiovascular research roles. Also, for the first time, the BHF will fund healthcare professionals, such as nurses, by establishing a de

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now